PL415635A1 - Concentration of zinc in blood and changes within GPX1 gene, as risk factors for breast or ovary cancers in carriers of BRCA1 mutation, subjected to the uterine adnexa removal operation - Google Patents

Concentration of zinc in blood and changes within GPX1 gene, as risk factors for breast or ovary cancers in carriers of BRCA1 mutation, subjected to the uterine adnexa removal operation

Info

Publication number
PL415635A1
PL415635A1 PL415635A PL41563515A PL415635A1 PL 415635 A1 PL415635 A1 PL 415635A1 PL 415635 A PL415635 A PL 415635A PL 41563515 A PL41563515 A PL 41563515A PL 415635 A1 PL415635 A1 PL 415635A1
Authority
PL
Poland
Prior art keywords
concentration
zinc
gpx1
breast
serum
Prior art date
Application number
PL415635A
Other languages
Polish (pl)
Inventor
Jan Lubiński
Anna Jakubowska
Wojciech Marciniak
Magdalena Muszyńska
Katarzyna Kaczmarek
Tomasz Huzarski
Jacek Gronwald
Cezary Cybulski
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL415635A priority Critical patent/PL415635A1/en
Publication of PL415635A1 publication Critical patent/PL415635A1/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

W zgłoszeniu stwierdzono, że występuje korelacja między genotypem genu GPX1 (rs 1050450), poziomem cynku w surowicy a ryzykiem raka piersi lub jajnika u nosicielek mutacji w genie BRCA1 poddanych w przeszłości zabiegowi usunięcia przydatków. Przedmiotem zgłoszenia jest sposób określenia ryzyka raka, charakteryzujący się tym, że obejmuje ocenę konstytucyjnej zmiany w genie GPX1 Pro200Leu (rs 1050450) oraz ocenę stężenia cynku w próbce biologicznej badanej nosicielki mutacji w genie BRCA1 poddanej adnexektomii, przy czym kombinacja poszczególnych genotypów z określonym stężeniem cynku wskazuje znacząco obniżone ryzyko rozwoju raków piersi lub jajnika: - dla genotypu GPX1 CC przy stężeniu cynku w surowicy ? 1025 µg/l (lub stężeniu w dowolnym materiale biologicznym odpowiadającym stężeniu w surowicy); - dla genotypu GPX1 nCC przy stężeniu cynku w surowicy 750-950 µg/l (lub stężeniu w dowolnym materiale biologicznym odpowiadającym stężeniu w surowicy).The report found that there was a correlation between the GPX1 gene genotype (rs 1050450), serum zinc levels and the risk of breast or ovarian cancer in carriers of the BRCA1 mutation who had undergone adnexectomy surgery in the past. The subject of the application is a method of determining the risk of cancer, characterized in that it includes the assessment of the constitutional change in the GPX1 Pro200Leu gene (rs 1050450) and the assessment of zinc concentration in the biological sample of the examined carrier of mutations in the BRCA1 gene subjected to adnexectomy, the combination of individual genotypes with a specific concentration of zinc indicates a significantly reduced risk of developing breast or ovarian cancers: - for GPX1 CC genotype at serum zinc? 1025 µg / l (or concentration in any biological material corresponding to the serum concentration); - for the GPX1 nCC genotype at a serum zinc concentration of 750-950 µg / l (or the concentration in any biological material corresponding to the serum concentration).

PL415635A 2015-12-30 2015-12-30 Concentration of zinc in blood and changes within GPX1 gene, as risk factors for breast or ovary cancers in carriers of BRCA1 mutation, subjected to the uterine adnexa removal operation PL415635A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL415635A PL415635A1 (en) 2015-12-30 2015-12-30 Concentration of zinc in blood and changes within GPX1 gene, as risk factors for breast or ovary cancers in carriers of BRCA1 mutation, subjected to the uterine adnexa removal operation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL415635A PL415635A1 (en) 2015-12-30 2015-12-30 Concentration of zinc in blood and changes within GPX1 gene, as risk factors for breast or ovary cancers in carriers of BRCA1 mutation, subjected to the uterine adnexa removal operation

Publications (1)

Publication Number Publication Date
PL415635A1 true PL415635A1 (en) 2017-07-03

Family

ID=59201371

Family Applications (1)

Application Number Title Priority Date Filing Date
PL415635A PL415635A1 (en) 2015-12-30 2015-12-30 Concentration of zinc in blood and changes within GPX1 gene, as risk factors for breast or ovary cancers in carriers of BRCA1 mutation, subjected to the uterine adnexa removal operation

Country Status (1)

Country Link
PL (1) PL415635A1 (en)

Similar Documents

Publication Publication Date Title
PH12019502558A1 (en) Diagnostic assays for detecting, quantifying, and/or tracking microbes and other analytes
MX2016004557A (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer.
MY195045A (en) Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer
MX2018000382A (en) Method for assessing cell surface receptors of blood cells.
Tabatabai et al. A new robust method for nonlinear regression
PL415635A1 (en) Concentration of zinc in blood and changes within GPX1 gene, as risk factors for breast or ovary cancers in carriers of BRCA1 mutation, subjected to the uterine adnexa removal operation
Eskandarion et al. Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis
NZ714014A (en) Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
PL415645A1 (en) Concentration of zinc in blood and changes within MMP1 gene as risk factors for cancers in women
PL415643A1 (en) Concentration of iron in blood and changes within GPX1 gene as risk factors for cancers in women
PL415646A1 (en) Concentration of copper in blood and changes within CAT gene as risk factors for cancers in women
PL415640A1 (en) Concentration of iron in blood and changes within HFE gene as risk factors for cancers in women
PL415632A1 (en) Concentration in blood and changes within IL6 gene as risk factors for cancers in women
PL415642A1 (en) Concentration of iron in blood and changes within HFE gene as risk factors for cancers in men
PL415639A1 (en) Concentration of iron in blood and changes within SEP15 gene as risk factors for cancers in women
PL415647A1 (en) Concentration of copper in blood as a risk factor for breast or ovary cancers in the carriers of a mutation in BRCA1 gene
PL414266A1 (en) Concentration of selenium in blood as a risk factor for cancers in women
PL414268A1 (en) Concentration of zinc in blood within IL6 gene as risk factors for cancers in women
PL415634A1 (en) Concentration of selenium in blood as a risk factor for cancers in men
MX2017004816A (en) Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis.
PL415636A1 (en) Concentration of iron in blood as a risk factor for cancers in men
GB201001950D0 (en) Infection prognostic assay
PL414267A1 (en) Concentration of iron in blood as a risk factor for cancers in women who are carriers of a mutation in BRCA1 gene
PL415644A1 (en) Concentration of iron in blood as a risk factor for cancers in women after the age of 50
PL414265A1 (en) Concentration of copper in blood as a risk factor for extramammary breast cancers in women